How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

264 results for

Adamantane

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

21. 5-(Adamantan-1-yl)-3-[(2-meth­oxy­eth­yl)sulfan­yl]-4-phenyl-4H-1,2,4-triazole (PubMed)

5-(Adamantan-1-yl)-3-[(2-meth­oxy­eth­yl)sulfan­yl]-4-phenyl-4H-1,2,4-triazole In the title adamantyl derivative, C(21)H(27)N(3)OS, the terminal meth-oxy-ethyl unit is disordered over two orientations with a refined site-occupancy ratio of 0.846 (6):0.154 (6). The 1,2,4-triazole ring is statistically planar [r.m.s. deviation = 0.002 (2) Å] and the phenyl substituent is almost perpendicular to its mean plane [dihedral angle = 83.57 (11)°]. No directional inter-molecular inter-actions were

Full Text available with Trip Pro

2012 Acta Crystallographica Section E: Structure Reports Online

22. Adamantane

Adamantane Adamantane Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Adamantane Adamantane Aka: Adamantane , Amantadine , Symmetrel (...) on antivirals in (2011) Images: Related links to external sites (from Bing) These images are a random sampling from a Bing search on the term "Adamantane." Click on the image (or right click) to open the source website in a new browser window. Related Studies (from Trip Database) Cost: Medications amantadine (on 5/17/2017 at ) AMANTADINE 100 MG CAPSULE Generic $1.03 each AMANTADINE 100 MG TABLET Generic $1.50 each AMANTADINE 50 MG/5 ML SOLUTION Generic $0.02 per ml FPNotebook does not benefit financially

2015 FP Notebook

23. (2SR,3RS)-Methyl 2-(adamantan-1-yl)-3-phenyl­sulfonyl-3-(pyridin-2-ylsulfan­yl)propano­ate dichloro­methane hemisolvate (PubMed)

(2SR,3RS)-Methyl 2-(adamantan-1-yl)-3-phenyl­sulfonyl-3-(pyridin-2-ylsulfan­yl)propano­ate dichloro­methane hemisolvate The title compound, C(25)H(29)NO(4)S(2) 0.5CH(2)Cl(2), was obtained as a racemate. The pyridine and phenyl rings are arranged face-to-face, giving a weak intra-molecular π-π inter-action [centroid-centroid separation = 3.759 (3) Å]. These inter-actions are extended inter-molecularly, forming chains of stacked rings along [001] with separations of 3.859 (3) and 3.916 (3) Å

Full Text available with Trip Pro

2011 Acta Crystallographica Section E: Structure Reports Online

24. Bis(μ-adamantane-1,3-dicarboxyl­ato-κ4 O 1,O 1′:O 3,O 3′)bis­[aqua­(3-carboxy­adam­antane-1-carboxyl­ato-κO 1)(1,10-phen­an­throline-κ2 N,N′)erbium(III)] dihydrate (PubMed)

Bis(μ-adamantane-1,3-dicarboxyl­ato-κ4 O 1,O 1′:O 3,O 3′)bis­[aqua­(3-carboxy­adam­antane-1-carboxyl­ato-κO 1)(1,10-phen­an­throline-κ2 N,N′)erbium(III)] dihydrate The asymmetric unit of the binuclear centrosymmetric title compound, [Er(2)(C(12)H(14)O(4))(2)(C(12)H(15)O(4))(2)(C(12)H(8)N(2))(2)(H(2)O)(2)]·2H(2)O, contains one Er(III) atom, one coordinated water mol-ecule, one 1,10-phenanthroline (phen) ligand, two differently coordinated adamantane-1,3-dicarboxyl-ate (H(2)L

Full Text available with Trip Pro

2011 Acta Crystallographica Section E: Structure Reports Online

25. Dual resistance to adamantanes and oseltamivir among seasonal influenza A(H1N1) viruses: 2008-2010. (PubMed)

Dual resistance to adamantanes and oseltamivir among seasonal influenza A(H1N1) viruses: 2008-2010. Two distinct genetic clades of seasonal influenza A(H1N1) viruses have cocirculated in the recent seasons: clade 2B oseltamivir-resistant and adamantane-susceptible viruses, and clade 2C viruses that are resistant to adamantanes and susceptible to oseltamivir. We tested seasonal influenza A(H1N1) viruses collected in 2008-2010 from the United States and globally for resistance to antivirals (...) approved by the Food and Drug Administration. We report 28 viruses with both adamantane and oseltamivir (dual) resistance from 5 countries belonging to 4 distinct genotypes. Because of limited options for antiviral treatment, emergence of dual-resistant influenza viruses poses a public health concern, and their circulation needs to be closely monitored.

Full Text available with Trip Pro

2011 Journal of Infectious Diseases

26. catena-Poly[[[aqua­(1,10-phenanthro­line)manganese(II)]-μ-adamantane-1,3-dicarboxyl­ato] monohydrate] (PubMed)

catena-Poly[[[aqua­(1,10-phenanthro­line)manganese(II)]-μ-adamantane-1,3-dicarboxyl­ato] monohydrate] In the title coordination polymer, {[Mn(C(12)H(14)O(4))(C(12)H(8)N(2))(H(2)O)]·H(2)O}(n), the Mn(II) atom has a highly distorted cis-MnN(2)O(4) octa-hedral geometry arising from its coordination by a bidentate phenanthroline ligand, a water mol-ecule and monodentate and bidentate adamantane-1,3-dicarboxyl-ate dianions. The bridging dianion leads to [001] chains in the crystal. The chains

Full Text available with Trip Pro

2011 Acta Crystallographica Section E: Structure Reports Online

27. 1-(1-Acetyl-piperidin-4-yl)-3-adamantan-1-yl-urea (AR9281) as a potent, selective, and orally available soluble epoxide hydrolase inhibitor with efficacy in rodent models of hypertension and dysglycemia (PubMed)

1-(1-Acetyl-piperidin-4-yl)-3-adamantan-1-yl-urea (AR9281) as a potent, selective, and orally available soluble epoxide hydrolase inhibitor with efficacy in rodent models of hypertension and dysglycemia 1-(1-Acetyl-piperidin-4-yl)-3-adamantan-1-yl-urea 14a (AR9281), a potent and selective soluble epoxide hydrolase inhibitor, was recently tested in a phase 2a clinical setting for its effectiveness in reducing blood pressure and improving insulin resistance in pre-diabetic patients. In a mouse

Full Text available with Trip Pro

2010 Bioorganic & medicinal chemistry letters

28. Adamantane resistance in seasonal human influenza A viruses from Calgary, Alberta (January 2007 to August 2008) (PubMed)

Adamantane resistance in seasonal human influenza A viruses from Calgary, Alberta (January 2007 to August 2008) The available antivirals for the treatment and prophylaxis of influenza A infections include the adamantanes (amantadine and rimantadine), which are matrix (M2) protein inhibitors, and the neuraminidase inhibitors (oseltamivir and zanamivir). Resistance to the adamantanes is conferred by mutations at amino acid positions 26, 27, 30, 31 or 34 within the M2 protein of influenza (...) A viruses. A significant increase in adamantane resistance has been reported worldwide since 2003, reflected by a similar increase in Canada. The present study reports on the frequency of adamantane resistance in seasonal influenza A viruses in Calgary, Alberta, for the period between January 2007 and August 2008, as an update to the previous report. Positive influenza A samples (221 original patient specimens and 34 isolates obtained by viral culture) were analyzed for changes in the critical amino

Full Text available with Trip Pro

2010 The Canadian Journal of Infectious Diseases & Medical Microbiology

29. A comprehensive surveillance of adamantane resistance among human influenza A virus isolated from mainland China between 1956 and 2009. (PubMed)

A comprehensive surveillance of adamantane resistance among human influenza A virus isolated from mainland China between 1956 and 2009. Adamantane-derived drugs have been used for treatment and prophylaxis of influenza A virus infection for many years worldwide. Rapid surveillance of antiviral drug resistance is important for appropriate clinical guideline development. Here, we retrospectively assessed adamantane resistance among different influenza A subtypes (H1N1, H3N2 and H5N1) over 53 (...) years (1956-2009) in mainland China.A total of 1,451 viruses, including 773 H3N2 viruses, 647 H1N1 viruses and 31 human H5N1 viruses, were analysed by matrix gene sequencing and assayed for drug resistance.Our results show that the prevalence of adamantane-resistant H3N2 viruses was low between 1956 and 2002, but substantially increased in 2003 to the extent that since 2006 all H3N2 viruses have been drug resistant. The percentage of adamantane-resistant H1N1 viruses also increased from 50.0

2010 Antiviral Therapy

30. Corticosteroids as adjunctive therapy in the treatment of influenza. (PubMed)

Corticosteroids as adjunctive therapy in the treatment of influenza. Specific treatments for influenza are limited to neuraminidase inhibitors and adamantanes. Corticosteroids show evidence of benefit in sepsis and related conditions, most likely due to their anti-inflammatory and immunomodulatory properties. Although commonly prescribed for severe influenza, there is uncertainty over their potential benefits or harms. This is an update of a review first published in 2016.To systematically

Full Text available with Trip Pro

2019 Cochrane

31. 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenza

as an alternative to antiviral chemoprophylaxis (C-III) . XI. Which antiviral drugs should be used for preexposure chemoprophylaxis for influenza? Clinicians should use an NAI (oral oseltamivir or inhaled zanamivir) if preexposure chemoprophylaxis for influenza is administered rather than an adamantane antiviral (A-II) . XII. What is the duration of preexposure antiviral chemoprophylaxis to prevent influenza? Clinicians should administer preexposure antiviral chemoprophylaxis for adults and children aged ≥3 (...) to antiviral treatment dosing in persons receiving postexposure antiviral chemoprophylaxis who become symptomatic, preferably with an antiviral drug with a different resistance profile if not contraindicated (A-III) . XVI. Which antiviral drugs should be used for postexposure chemoprophylaxis? Clinicians should administer an NAI (inhaled zanamivir or oral oseltamivir) if postexposure chemoprophylaxis for influenza is given, rather than an adamantane antiviral (A-II) . Institutional Outbreak Control XVII

2019 Infectious Diseases Society of America

32. Peramivir (Alpivab) - Influenza, Human

. There are no licensed intravenous presentations of neuraminidase inhibitors in the EU although these may be available for compassionate use in severely ill patients, in whom their efficacy has not been established. Otherwise, treatment for severe influenza is supportive and may involve the need for assisted ventilation, circulatory support and antibacterial agents to treat or prevent secondary bacterial infections, such as staphylococcal pneumonia. In some countries amantadine and rimantadine (the adamantanes

2018 European Medicines Agency - EPARs

34. [Saxagliptin/metformin (type 2 diabetes) - benefit assessment according to õ35a Social Code Book V]

(type 2 diabetes) - benefit assessment according to §35a Social Code Book V] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG-Berichte 554. 2017 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Humans; Metformin; saxagliptin Language Published German Country of organisation Germany English summary There is no English language summary available. Address for correspondence IQWiG, Im

2018 Health Technology Assessment (HTA) Database.

35. Corticosteroids as adjunctive therapy in the treatment of influenza. (PubMed)

Corticosteroids as adjunctive therapy in the treatment of influenza. Specific treatments for influenza are limited to neuraminidase inhibitors and adamantanes. Corticosteroids show evidence of benefit in sepsis and related conditions, most likely due to their anti-inflammatory and immunomodulatory properties. Although commonly prescribed for severe influenza, there is uncertainty over their potential benefit or harm.To systematically assess the effectiveness and potential adverse effects

Full Text available with Trip Pro

2016 Cochrane

36. [Saxagliptin / metformin - benefit assessment according to õ 35a Social Code Book V]

; Auftrag A16-4. [Saxagliptin / metformin - benefit assessment according to § 35a Social Code Book V] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG-Berichte 44. 2016 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Adamantane; Dipeptides; Germany; Humans; Metformin; State Medicine Language Published German Country of organisation Germany English summary There is no English language summary available. Address for correspondence IQWiG

2017 Health Technology Assessment (HTA) Database.

37. [Saxagliptin - benefit assessment according to õ35a Social Code Book V]

Code Book V] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG-Berichte 442. 2016 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Adamantane; Dipeptides; Humans Language Published German Country of organisation Germany English summary There is no English language summary available. Address for correspondence IQWiG, Im Mediapark 8, DE-50670 Cologne, GERMANY, Tel: +49 (0) 221 - 35685 - 0, Fax: +49 (0) 221 - 35685 - 1 Email: berichte

2017 Health Technology Assessment (HTA) Database.

38. CRACKCast E130 – Viruses

by inhibiting the release of viral progeny from infected cells. These drugs are active against both influenza A and B. Amantadine and rimantadine are the currently available adamantane antivirals. – they are NOT recommended because influenza strains are 90% resistant to them . Start them ASAP ( don ’ t wait for testing ) – ideally within 48 hrs of onset . From Uptodate : “ Adults with mild illness without high – risk conditions who are younger than 65 years of age do not require testing or treatment

2017 CandiEM

39. Adamantane-1-thio­amide (PubMed)

Adamantane-1-thio­amide The title compound, C(11)H(17)NS, is an important inter-mediate for the synthesis of biologically active adamantlythia-zolo-oxadiazo-les. The adamantyl residue is disordered about a twofold rotation axis over two sites with site-occupation factors of 0.817 (3) and 0.183 (3). The crystal structure is stabilized by inter-molecular N-H⋯S hydrogen-bonding inter-actions.

Full Text available with Trip Pro

2009 Acta Crystallographica Section E: Structure Reports Online

40. 2,5-Dioxopyrrolidin-1-yl adamantane-1-carboxyl­ate (PubMed)

2,5-Dioxopyrrolidin-1-yl adamantane-1-carboxyl­ate The title compound, C(15)H(19)NO(4), contains one crystallographically independent mol-ecule in the asymmetric unit. The N-O-C-O torsion angle is 1.97 (9)°. The two pairs of vicinal H atoms that lie above or below the plane defined by the five-membered pyrrolidine-2,5-dione ring are an average of 6.57 (5)° from being eclipsed. The average absolute C-C-C-C torsion angle in the adamantane skeleton, in which each fused cyclo-hexane ring

Full Text available with Trip Pro

2009 Acta Crystallographica Section E: Structure Reports Online

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>